While injectable GLP-1 medications demonstrate significant weight loss of 10-20% through FDA-approved formulations, patches have no substantial evidence supporting their effectiveness
Development of antiobesity medication has not been easy, because of unexpected adverse events
Reconstituting tirzepatide intimidates even experienced researchers, and for good reason
The Results Participants receiving 7.2 mg semaglutide achieved a mean weight loss of 20.7% at 72 weeks, compared to 17.5% in the 2.4 mg group, and 2.4% in the placebo group. Over 30% of participants on the 7.2 mg dose lost 25% or more of their body weight
I have good erections, but it still bothers me
In humans, C-cells contain far fewer GLP-1 receptors, which suggests a much lower risk for similar outcomes